SARS-CoV-2 neutralizing antibody therapies: an early retrospective cohort study of 26 hospitalized patients treated with bamlanivimab or casirivimab/imdevimab
Objectives: In this early retrospective cohort study, a total of 26 patients with SARS-CoV-2 were treated with bamlanivimab or casirivimab/imdevimab, and the reduction of the viral load associated with the developed clinical symptoms was analyzed. Methods: Patients in the intervention groups receive...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-04-01
|
| Series: | International Journal of Infectious Diseases |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1201971223000127 |
| _version_ | 1827987877335662592 |
|---|---|
| author | Martin Heller Clara Henrici Judith Büttner Sebastian Leube Isabelle Treske Petra Pospischil Michael Doll Ilka Schanz Agnes Hallier Eva Herrmann Michael Schmidt Christoph Sarrazin |
| author_facet | Martin Heller Clara Henrici Judith Büttner Sebastian Leube Isabelle Treske Petra Pospischil Michael Doll Ilka Schanz Agnes Hallier Eva Herrmann Michael Schmidt Christoph Sarrazin |
| author_sort | Martin Heller |
| collection | DOAJ |
| description | Objectives: In this early retrospective cohort study, a total of 26 patients with SARS-CoV-2 were treated with bamlanivimab or casirivimab/imdevimab, and the reduction of the viral load associated with the developed clinical symptoms was analyzed. Methods: Patients in the intervention groups received bamlanivimab or casirivimab/imdevimab. Patients without treatment served as control. Outcomes were assessed by clinical symptoms and change in log viral load from baseline based on the cycle threshold over a period of 18 days. Results: Median log viral load decline was higher in both intervention groups after 3 and 6 days compared to control. However, at later time points, the decline of the viral load was more distinct in the control group. Mild symptoms of COVID-19 were observed in 6.3% of the intervention groups and in no patient of the control. No patients treated with bamlanivimab, 18.8% treated with casirivimab/imdevimab, and 14.2% in the control group developed moderate symptoms. Severe symptoms were recorded only in the control group (14.2%), including one related death. Conclusion: Treatment with monoclonal SARS-CoV-2 antibodies seems to accelerate decline of virus loads, especially in the first 6 days after administration, compared to control. This may be associated with a reduced likeliness of a severe course of COVID-19. |
| first_indexed | 2024-04-09T23:54:59Z |
| format | Article |
| id | doaj.art-b89c38cffdf0416ba36498e3a5265dba |
| institution | Directory Open Access Journal |
| issn | 1201-9712 |
| language | English |
| last_indexed | 2024-04-09T23:54:59Z |
| publishDate | 2023-04-01 |
| publisher | Elsevier |
| record_format | Article |
| series | International Journal of Infectious Diseases |
| spelling | doaj.art-b89c38cffdf0416ba36498e3a5265dba2023-03-17T04:32:42ZengElsevierInternational Journal of Infectious Diseases1201-97122023-04-01129260265SARS-CoV-2 neutralizing antibody therapies: an early retrospective cohort study of 26 hospitalized patients treated with bamlanivimab or casirivimab/imdevimabMartin Heller0Clara Henrici1Judith Büttner2Sebastian Leube3Isabelle Treske4Petra Pospischil5Michael Doll6Ilka Schanz7Agnes Hallier8Eva Herrmann9Michael Schmidt10Christoph Sarrazin11Department of Gastroenterology and Infectiology, Medical Clinic, St. Josefs-Hospital Wiesbaden, Wiesbaden, Germany; Corresponding author.Department of Gastroenterology and Infectiology, Medical Clinic, St. Josefs-Hospital Wiesbaden, Wiesbaden, GermanyDepartment of Gastroenterology and Infectiology, Medical Clinic, St. Josefs-Hospital Wiesbaden, Wiesbaden, GermanyDepartment of Cardiology, Medical Clinic, St. Josefs-Hospital Wiesbaden, Wiesbaden, GermanyDepartment of Cardiology, Medical Clinic, St. Josefs-Hospital Wiesbaden, Wiesbaden, GermanyDepartment of Gastroenterology and Infectiology, Medical Clinic, St. Josefs-Hospital Wiesbaden, Wiesbaden, GermanyDepartment of Gastroenterology and Infectiology, Medical Clinic, St. Josefs-Hospital Wiesbaden, Wiesbaden, GermanyDepartment of Interdisciplinary Intensive Care, Medical Clinic, St. Josefs-Hospital Wiesbaden, Wiesbaden, GermanyDepartment of Emergency Medicine, St. Josefs-Hospital Wiesbaden, Wiesbaden, GermanyInstitute for Biostatistics and Mathematical Modeling, Universitätsklinikum der Goethe-Universität Frankfurt, Frankfurt am Main, GermanyBlutspendedienst, DRK Baden-Württemberg – Hessen Gesellschaft mit beschränkter Haftung, Frankfurt GermanyDepartment of Gastroenterology and Infectiology, Medical Clinic, St. Josefs-Hospital Wiesbaden, Wiesbaden, GermanyObjectives: In this early retrospective cohort study, a total of 26 patients with SARS-CoV-2 were treated with bamlanivimab or casirivimab/imdevimab, and the reduction of the viral load associated with the developed clinical symptoms was analyzed. Methods: Patients in the intervention groups received bamlanivimab or casirivimab/imdevimab. Patients without treatment served as control. Outcomes were assessed by clinical symptoms and change in log viral load from baseline based on the cycle threshold over a period of 18 days. Results: Median log viral load decline was higher in both intervention groups after 3 and 6 days compared to control. However, at later time points, the decline of the viral load was more distinct in the control group. Mild symptoms of COVID-19 were observed in 6.3% of the intervention groups and in no patient of the control. No patients treated with bamlanivimab, 18.8% treated with casirivimab/imdevimab, and 14.2% in the control group developed moderate symptoms. Severe symptoms were recorded only in the control group (14.2%), including one related death. Conclusion: Treatment with monoclonal SARS-CoV-2 antibodies seems to accelerate decline of virus loads, especially in the first 6 days after administration, compared to control. This may be associated with a reduced likeliness of a severe course of COVID-19.http://www.sciencedirect.com/science/article/pii/S1201971223000127COVID-19BamlanivimabCasirivimabImdevimabAntibody therapyViral load |
| spellingShingle | Martin Heller Clara Henrici Judith Büttner Sebastian Leube Isabelle Treske Petra Pospischil Michael Doll Ilka Schanz Agnes Hallier Eva Herrmann Michael Schmidt Christoph Sarrazin SARS-CoV-2 neutralizing antibody therapies: an early retrospective cohort study of 26 hospitalized patients treated with bamlanivimab or casirivimab/imdevimab International Journal of Infectious Diseases COVID-19 Bamlanivimab Casirivimab Imdevimab Antibody therapy Viral load |
| title | SARS-CoV-2 neutralizing antibody therapies: an early retrospective cohort study of 26 hospitalized patients treated with bamlanivimab or casirivimab/imdevimab |
| title_full | SARS-CoV-2 neutralizing antibody therapies: an early retrospective cohort study of 26 hospitalized patients treated with bamlanivimab or casirivimab/imdevimab |
| title_fullStr | SARS-CoV-2 neutralizing antibody therapies: an early retrospective cohort study of 26 hospitalized patients treated with bamlanivimab or casirivimab/imdevimab |
| title_full_unstemmed | SARS-CoV-2 neutralizing antibody therapies: an early retrospective cohort study of 26 hospitalized patients treated with bamlanivimab or casirivimab/imdevimab |
| title_short | SARS-CoV-2 neutralizing antibody therapies: an early retrospective cohort study of 26 hospitalized patients treated with bamlanivimab or casirivimab/imdevimab |
| title_sort | sars cov 2 neutralizing antibody therapies an early retrospective cohort study of 26 hospitalized patients treated with bamlanivimab or casirivimab imdevimab |
| topic | COVID-19 Bamlanivimab Casirivimab Imdevimab Antibody therapy Viral load |
| url | http://www.sciencedirect.com/science/article/pii/S1201971223000127 |
| work_keys_str_mv | AT martinheller sarscov2neutralizingantibodytherapiesanearlyretrospectivecohortstudyof26hospitalizedpatientstreatedwithbamlanivimaborcasirivimabimdevimab AT clarahenrici sarscov2neutralizingantibodytherapiesanearlyretrospectivecohortstudyof26hospitalizedpatientstreatedwithbamlanivimaborcasirivimabimdevimab AT judithbuttner sarscov2neutralizingantibodytherapiesanearlyretrospectivecohortstudyof26hospitalizedpatientstreatedwithbamlanivimaborcasirivimabimdevimab AT sebastianleube sarscov2neutralizingantibodytherapiesanearlyretrospectivecohortstudyof26hospitalizedpatientstreatedwithbamlanivimaborcasirivimabimdevimab AT isabelletreske sarscov2neutralizingantibodytherapiesanearlyretrospectivecohortstudyof26hospitalizedpatientstreatedwithbamlanivimaborcasirivimabimdevimab AT petrapospischil sarscov2neutralizingantibodytherapiesanearlyretrospectivecohortstudyof26hospitalizedpatientstreatedwithbamlanivimaborcasirivimabimdevimab AT michaeldoll sarscov2neutralizingantibodytherapiesanearlyretrospectivecohortstudyof26hospitalizedpatientstreatedwithbamlanivimaborcasirivimabimdevimab AT ilkaschanz sarscov2neutralizingantibodytherapiesanearlyretrospectivecohortstudyof26hospitalizedpatientstreatedwithbamlanivimaborcasirivimabimdevimab AT agneshallier sarscov2neutralizingantibodytherapiesanearlyretrospectivecohortstudyof26hospitalizedpatientstreatedwithbamlanivimaborcasirivimabimdevimab AT evaherrmann sarscov2neutralizingantibodytherapiesanearlyretrospectivecohortstudyof26hospitalizedpatientstreatedwithbamlanivimaborcasirivimabimdevimab AT michaelschmidt sarscov2neutralizingantibodytherapiesanearlyretrospectivecohortstudyof26hospitalizedpatientstreatedwithbamlanivimaborcasirivimabimdevimab AT christophsarrazin sarscov2neutralizingantibodytherapiesanearlyretrospectivecohortstudyof26hospitalizedpatientstreatedwithbamlanivimaborcasirivimabimdevimab |